Back to results
US 11,590,171 B2Granted
Targeted replacement of endogenous T cell receptors
AssigneeThe Regents of the University of California
InventorsTheodore Lee Roth, Eric Shifrut, Alexander Marson, Cristina Puig Saus, Antoni Ribas
Life of this patent
Estimating the term…
Abstract
Provided herein are methods and compositions for editing the genome of a human T cell. In some embodiments, a heterologous T cell receptor (TCR)-β chain and a heterologous TCR-α chain are inserted into exon 1 of a TCR subunit constant gene in the genome of the T cell.
Claims16
A modified primary human T cell comprising:
- at least one nucleic acid sequence comprising at least one heterologous gene non-virally inserted into one or both of:
- an endogenous T cell receptor alpha subunit constant gene (TRAC);
- and
- an endogenous T cell receptor beta subunit constant gene (TRBC), wherein the at least one heterologous gene encodes at least one antigen-specific receptor that specifically binds the target antigen expressed by a cancer, and wherein the at least one nucleic acid sequence is at least 500 bp in size.
1 more element
Dependencies are inferred from the claim text.